Biomerica, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.6M
- Price
- $1.88
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.57%
- Volume
- 1.9K
About
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Quick stats
Shares outstanding4.6M
Computed float2.6M
Float / shares55.6%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000073290
Websitehttps://www.biomerica.com
AI Summary
AI-generated1/8
standardbullishearnings
Biomerica Reports Fiscal 2026 Year-End Financial Results
Biomerica reported fiscal 2026 revenue of $4.50 million, down from $5.30 million in the prior year, while its net loss narrowed 24% to $3.8 million or $(1.30) per share.
Operationally, the company confirmed that 100% of valid Medicare claims for its InFoods IBS test have been paid at the full $300 rate, and it secured a $1.75 million CDMO agreement to develop proprietary IVD assays.
Subsequent to year-end, Biomerica closed a $2.23 million private placement at $1.60 per share and engaged B. Riley Securities to explore strategic alternatives including partnerships and business combinations.
Red flags
- Cash position declined to $1.3 million from $2.4 million year-over-year
- Full-year revenue decreased from $5.30 million to $4.50 million